NI201300007A - A NEW CONJUGATE OF COLOGNE GRANULOCITE - STIMULATING FACTOR (G -CSF) WITH POLYETHYLENE GLYCOL. - Google Patents

A NEW CONJUGATE OF COLOGNE GRANULOCITE - STIMULATING FACTOR (G -CSF) WITH POLYETHYLENE GLYCOL.

Info

Publication number
NI201300007A
NI201300007A NI201300007A NI201300007A NI201300007A NI 201300007 A NI201300007 A NI 201300007A NI 201300007 A NI201300007 A NI 201300007A NI 201300007 A NI201300007 A NI 201300007A NI 201300007 A NI201300007 A NI 201300007A
Authority
NI
Nicaragua
Prior art keywords
csf
stimulating factor
conjugate
granulocite
cologne
Prior art date
Application number
NI201300007A
Other languages
Spanish (es)
Inventor
Veniaminovna Chernovskaya Tatyana
Alexandrovich Denisov Lev
Valentinovich Morozov Dmitriy
Georgievna Rudenko Elena
Leonidovna Morozova Elena
Original Assignee
Closed Join Stock Company Biocad
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45567857&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201300007(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Closed Join Stock Company Biocad filed Critical Closed Join Stock Company Biocad
Publication of NI201300007A publication Critical patent/NI201300007A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Abstract

La presente invención se relaciona a farmacéuticos y medicinas, específicamente, a un nuevo conjugado fisiológicamente de granulocita colonia estimulante factor (G -CSF) con la fórmula general: (I) Donde: n - intergers de 681 a 1,000; m - interger 4; NªH - G - CSF - Natural o recombinante polipéptido, teniendo actividad de G - CSF. La invención También está relacionada a medicinas conteniendo el conjugado reclamado de fórmula (1), composiciones farmacéuticas, el uso de conjugado de fórmula (1) para drogas y medicinas con granulocita colonia estimulante factor como un ingrediente activo, se aproxima a prevenir y/o tratar la neutropenia, el contenedor que contiene la composición farmacéutica.The present invention relates to pharmaceuticals and medicines, specifically, to a new physiologically conjugate of granulocyte colony stimulating factor (G -CSF) with the general formula: (I) Where: n - intergers from 681 to 1,000; m - interger 4; NªH-G-CSF-Natural or recombinant polypeptide, having G-CSF activity. The invention is also related to medicines containing the claimed conjugate of formula (1), pharmaceutical compositions, the use of conjugate of formula (1) for drugs and medicines with granulocyte colony stimulating factor as an active ingredient, approaches to prevent and / or treat neutropenia, the container containing the pharmaceutical composition.

NI201300007A 2010-08-13 2013-01-18 A NEW CONJUGATE OF COLOGNE GRANULOCITE - STIMULATING FACTOR (G -CSF) WITH POLYETHYLENE GLYCOL. NI201300007A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2010133875/10A RU2446173C1 (en) 2010-08-13 2010-08-13 New functional, high-purity stable conjugate of granulocyte colony-stimulating factor (g-csf) and polyethylene glycol with prolonged biological action, applicable for medical purposes, and based immunobiological agent

Publications (1)

Publication Number Publication Date
NI201300007A true NI201300007A (en) 2014-05-26

Family

ID=45567857

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201300007A NI201300007A (en) 2010-08-13 2013-01-18 A NEW CONJUGATE OF COLOGNE GRANULOCITE - STIMULATING FACTOR (G -CSF) WITH POLYETHYLENE GLYCOL.

Country Status (17)

Country Link
KR (1) KR101549457B1 (en)
CN (1) CN103140499B (en)
CL (1) CL2013000400A1 (en)
CO (1) CO6670557A2 (en)
CR (1) CR20130020A (en)
CU (1) CU24139B1 (en)
DO (1) DOP2013000003A (en)
EA (1) EA019043B1 (en)
EC (1) ECSP13012399A (en)
MA (1) MA34525B1 (en)
MY (1) MY160732A (en)
NI (1) NI201300007A (en)
PE (1) PE20131085A1 (en)
RS (1) RS20130094A1 (en)
RU (1) RU2446173C1 (en)
SG (1) SG187572A1 (en)
WO (1) WO2012021088A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012110057A1 (en) 2011-02-15 2012-08-23 Chemisches Institut Schaefer Ag Cefuroxime safety kit
AU2013270674B2 (en) 2012-06-07 2017-12-07 Children's Hospital Los Angeles Methods for treating neutropenia using retinoid agonists
CN103908427B (en) * 2013-01-05 2014-12-17 石药集团百克(山东)生物制药有限公司 Polyethylene glycol modified rhG-CSF injection and preparation method thereof
RU2535002C2 (en) * 2013-04-04 2014-12-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Method for correction of remote consequences of spermatogenesis caused by cytostatic exposure
MX2016010699A (en) 2014-02-18 2017-10-11 Children's Hospital Los Angeles Compositions and methods for treating neutropenia.
MX2017000467A (en) 2014-07-14 2017-07-28 Gennova Biopharmaceuticals Ltd A novel process for purification of rhu-gcsf.
IL247369B (en) * 2016-08-18 2018-08-30 B G Negev Tech And Applications Ltd Modified m-csf polypeptides and use thereof
KR102020995B1 (en) * 2017-10-30 2019-09-16 한국코러스 주식회사 A method of preparing gcsf and polyol_conjugated conjugates with high yield
US20230201307A1 (en) * 2020-03-17 2023-06-29 Drugrecure Aps Liquid formulation of gm-csf for inhalation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0401384B1 (en) * 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
KR20040083268A (en) * 2003-03-21 2004-10-01 한미약품 주식회사 Human granulocyte-colony stimulating factor conjugate having enhanced stability in blood and process for the preparation thereof
RU2278870C2 (en) * 2004-08-30 2006-06-27 Закрытое Акционерное Общество "Биокад" Method for preparing, isolating, purifying and stabilizing human recombinant granulocytic colony-stimulating factor useful for medicinal using and immunobiological agent based on thereof
MX2008009125A (en) * 2006-01-18 2008-10-23 Qps Llc Pharmaceutical compositions with enhanced stability.
EP2044097A4 (en) * 2006-06-23 2010-10-06 Quintessence Biosciences Inc Modified ribonucleases

Also Published As

Publication number Publication date
EA201101035A1 (en) 2012-02-28
KR101549457B1 (en) 2015-09-02
PE20131085A1 (en) 2013-10-10
RS20130094A1 (en) 2013-08-30
CO6670557A2 (en) 2013-05-15
CR20130020A (en) 2013-02-20
CL2013000400A1 (en) 2013-07-26
CN103140499B (en) 2014-12-17
CU20130012A7 (en) 2013-04-19
CU24139B1 (en) 2015-12-23
DOP2013000003A (en) 2013-07-31
MY160732A (en) 2017-03-15
CN103140499A (en) 2013-06-05
ECSP13012399A (en) 2013-05-31
WO2012021088A1 (en) 2012-02-16
SG187572A1 (en) 2013-03-28
KR20130043167A (en) 2013-04-29
EA019043B1 (en) 2013-12-30
MA34525B1 (en) 2013-09-02
RU2446173C1 (en) 2012-03-27

Similar Documents

Publication Publication Date Title
NI201300007A (en) A NEW CONJUGATE OF COLOGNE GRANULOCITE - STIMULATING FACTOR (G -CSF) WITH POLYETHYLENE GLYCOL.
BR112015005972A2 (en) benzoimidazole carboxylic acid amide type derivatives as apj receptor modulators
BR112013003045A2 (en) compound and pharmaceutical composition and uses thereof, sterile container and method for preparing pharmaceutical composition for administration
BR112013031268A8 (en) polypeptides
TN2015000187A1 (en) Triazolopyrazine
MX2013000821A (en) New aminopyrazoloquinazolines.
TR201904614T4 (en) Novel pyrazole derivative.
EA201690102A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING DIMETHYLFUMATE FOR INTRODUCTION TO LOW DAILY DOSE
UA109010C2 (en) Morpholino pyrividines and their use in therapy
CR20130588A (en) HALOGENOALQUIL-1,3-OXAZINAS AS INHIBITORS OF THE BACE1 AND / OR BACE 2
EA201401351A1 (en) DERIVATIVES OF BENZIMIDAZOL-PROLINE
EA201201050A1 (en) PYRAZOLES AS AN ANTAGONISTS CRTH2
MX2014013095A (en) Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc.
MX345238B (en) (alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases.
BR112015000578A2 (en) complement pathway modulators and their uses
BR112012024712A2 (en) trpv1 vanilloid receptor antagonists with a bicyclic moiety
BR112014015630A8 (en) fluoromethyl-5,6-dihydro-4h- [1,3] oxazins, their uses, and pharmaceutical composition
PH12014502619A1 (en) Novel dosage and formulation
EA201300857A1 (en) PYRAZOLES AS AN ANTAGONISTS CRTH2
BR112013006651A2 (en) composition and cocrystal of l-proline aprepitant
CY1115600T1 (en) Piperazines as Anthelmintic Agents
MX369508B (en) New thio derivatives bearing lactams as potent hdac inhibitors and their uses as medicaments.
MX2012010707A (en) Water-soluble pharmaceut.
BR112012020415A2 (en) pharmaceutical composition for the prevention or treatment of osteoarthritis
AR074470A1 (en) AMIDA COMPOUND OF THE CYCLOPROPANOCARBOXYL ACID, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF DIABETES